I’m invested here & I also noted in the prospectus that patent for LEAP applied for. So for me this was of interest to look into also, extensively, so thanks for posting the patent information here. I know you said you’d had a quick look, so not to be rude in anyway, as I know science is your field and respect you as a poster, but the 2 references you posted used (IAC) so Immunoaffinity Capture as well as other techniques discussed, so I’m going to focus on the difference between IAC & AC. IAC requires capture by a bead treated with antibodies that bind to specific proteins on the Exosomes, so a target protein. Not all Exosomes carry these target proteins.
LEAP program uses a different technique (AC) so affinity capture in that ligands bind to the membrane of the Exosomes, so this is different in that it’s not relying on a particular protein to bind to, but the membrane itself. So the capture will not be affected by target proteins. The technology is novel in this sense, so please revisit the IP & patent applied for, it’s very intense reading, but you of a lot will understand it. .
This process allows Exosomes to be extracted, separated from the substrate & processed in a sterile environment. Something you need for treating humans & clinical trials, rather than an in vivo lab environment where simpler extraction techniques with less Exosomes such as IAC & ultracentrifugation may be acceptable for these needs.
I apologise if this is simplified, but it’s how I understand things. GLTA
EX1 Price at posting:
55.0¢ Sentiment: Buy Disclosure: Held
.
